Glioma: Immunotherapeutic Approaches

Front Cover
ryuya yamanaka
Springer Science & Business Media, May 27, 2012 - Medical - 232 pages
0 Reviews
Treatment of glioma is currently one of the most challenging problems in oncology, as well as in neurosurgery. Despite major advances in our understanding of the pathomechanism, diagnosis by imaging and the availability of powerful therapeutic tools, the life expectancy of patients with glioblastoma has only been slightly prolonged and a cure remains elusive. None of the currently available surgical tools, including operative microscopes, lasers and image-guided surgery, can enable the detection and removal of all of the tumor tissue. In recent years, however, the landscape has been changing immeasurably, and molecular studies over the past two decades have identified a variety of genetic aberrations that are specifically associated with individual types of gliomas. In addition, certain molecular abnormalities have been linked to therapy responses, thereby establishing clinical biomarkers and molecular targets, and the use of novel agents is being investigated. These agents have been specifically engineered to exert specific cytotoxicity against gliomas, either on their own as single agents or in combination with other modalities. Moreover, there has been an enormous surge of interest in the area of immunology and immunotherapy, which has been facilitated by our understanding of the molecular basis of gliomas. Although several kinds of immunotherapeutic trials have been undertaken, we still await a great breakthrough in terms of clinical efficacy to prolong the survival time of glioma patients.
 

What people are saying - Write a review

We haven't found any reviews in the usual places.

Contents

CHAPTER 1 MOLECULAR BIOLOGY OF GLIOMA
2
CHAPTER 2 RECENT SURGICAL MANAGEMENT OF GLIOMAS
12
CHAPTER 3 RECENT MEDICAL MANAGEMENT OF GLIOBLASTOMA
26
PART II GLIOMA IMMUNOLOGY
41
CHAPTER 4 BASIC CONCEPTS IN GLIOMA IMMUNOLOGY
42
CHAPTER 5 MECHANISMS OF IMMUNE EVASION BY GLIOMAS
53
CHAPTER 6 GLIOMA ANTIGEN
77
PART III CYTOKINE SEROTHERAPY ADOPTIVE TRANSFER AND OTHER STRATEGIES
85
PART IV ACTIVE IMMUNOTHERAPY
142
CHAPTER 11 ANIMAL MODELS FOR VACCINE THERAPY
143
CHAPTER 12 IMMUNOGENE THERAPY
151
CHAPTER 13 PEPTIDE VACCINE
166
CHAPTER 14 ACTIVE IMMUNOTHERAPY Oncolytic Virus Therapy Using HSV1
178
CHAPTER 15 DENDRITIC CELL VACCINES
187
PART V NOVEL TOPICS
201
CHAPTER 16 ANTIGENRECEPTOR GENEMODIFIED T CELLS FOR TREATMENT OF GLIOMA
202

CHAPTER 7 CYTOKINE THERAPY
86
CHAPTER 8 IMMUNOTHERAPEUTIC APPROACH WITH OLIGODEOXYNUCLEOTIDES CONTAINING CpG MOTIFS CpGODN IN MALIGN...
95
CHAPTER 9 ADOPTIVE CELL TRANSFER THERAPY FOR MALIGNANT GLIOMAS
109
CHAPTER 10 MONOCLONAL ANTIBODY THERAPY FOR MALIGNANT GLIOMA
121
CHAPTER 17 GLIOMA STEM CELL RESEARCH FOR THE DEVELOPMENT OF IMMUNOTHERAPY
216
INDEX
227
Copyright

Other editions - View all

Common terms and phrases

About the author (2012)

RYUYA YAMANAKA is now a Professor at Kyoto Prefectural University of Medicine, Kyoto, Japan. He earned his MD at Niigata University, Japan, in 1982 and completed a neurosurgical residency training at its affiliated hospitals. He received his academic degree (Dr Med Sci) from Niigata University. Following research fellowships at the National Institutes of Health in the United States from 1994 to 1998, he assumed the position of Assistant Professor and Lecturer at the Department of Neurosurgery in the Brain Research Institute at Niigata University. In 2006, he was promoted to Professor of the Research Center of Innovative Cancer Therapy at Kurume University School of Medicine. He joined the faculty at Kyoto Prefectural University of Medicine in 2010. His main research interests include translational biochemical research in clinical oncology, including brain tumors. He is a member of international and national scientific organizations, including the American Association for Cancer Research (AACR ), American Society of Clinical Oncology (ASCO), Japanese Cancer Association (JCA), Japanese Society of Medical Oncology (JSMO) and Japan Neurosurgical Society (JNS). He has board certifications for Medical Oncology, Neurosurgery, Stroke and Cerebrovascular Diseases.

Bibliographic information